0001178913-18-000263.txt : 20180124 0001178913-18-000263.hdr.sgml : 20180124 20180124202422 ACCESSION NUMBER: 0001178913-18-000263 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180101 FILED AS OF DATE: 20180124 DATE AS OF CHANGE: 20180124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Domzalski David CENTRAL INDEX KEY: 0001727794 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36621 FILM NUMBER: 18546457 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001606645 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 BUSINESS PHONE: 97289316233 MAIL ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 FORMER COMPANY: FORMER CONFORMED NAME: Foamix Ltd. DATE OF NAME CHANGE: 20140428 4 1 a1821071.xml OWNERSHIP DOCUMENT X0306 4 2018-01-01 0 0001606645 Foamix Pharmaceuticals Ltd. FOMX 0001727794 Domzalski David C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK REHOVOT L3 7670402 ISRAEL 1 1 0 0 CEO Ordinary Shares 2018-01-01 4 M 0 5948 0.00 A 142819 D Ordinary Shares 2018-01-02 4 F 0 2397 5.98 D 140422 D Restricted Share Units 0.00 2018-01-01 4 M 0 5948 0.0 D Ordinary Shares 5948 0 D This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 23,192 ordinary shares previously reported in Table I of the reporting person's Form 3, (ii) 5,948 ordinary shares underlying restricted share units that vested on January 1, 2018 and (ii) 113,679 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security. The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of restricted share units. The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021. This class of restricted share units is included in Column 5 of Table I above. /s/ Ilan Hadar as attorney-in-fact for David Domzalski 2018-01-24